On December 12, 2024, Conduit Pharmaceuticals entered into a Services Agreement with SARBORG Limited to leverage AI and cybernetics for optimizing drug development processes. The agreement spans 12 months with potential extensions and includes three phases: Initial (0-24 weeks), Development (24-36 weeks), and Ongoing Services (36-52 weeks).SARBORG will provide algorithmic and cybernetic technology services, developing decision-support tools and advanced systems to enhance Conduit's decision-making and maximize its pharmaceutical asset portfolio value. Conduit will pay SARBORG an initial $200,000 in cash and $200,000 in stock (2,272,727 shares), with potential milestone payments up to $1.8M. Dr. Andrew Regan, a Conduit board member, also sits on SARBORG's board.The partnership aims to revolutionize Conduit's approach to drug development, potentially reducing human error, cutting costs, and improving efficiency across drug repurposing, discovery, and clinical trial monitoring. This AI-driven strategy is expected to accelerate growth, deliver shareholder value, and maintain Conduit's competitive edge in the pharmaceutical sector.

On December 12, 2024, Conduit Pharmaceuticals entered into a Services Agreement with SARBORG Limited to leverage AI and cybernetics for optimizing drug development processes. The agreement spans 12 months with potential extensions and includes three phases: Initial (0-24 weeks), Development (24-36 weeks), and Ongoing Services (36-52 weeks).SARBORG will provide algorithmic and cybernetic technology services, developing decision-support tools and advanced systems to enhance Conduit's decision-making and maximize its pharmaceutical asset portfolio value. Conduit will pay SARBORG an initial $200,000 in cash and $200,000 in stock (2,272,727 shares), with potential milestone payments up to $1.8M. Dr. Andrew Regan, a Conduit board member, also sits on SARBORG's board.The partnership aims to revolutionize Conduit's approach to drug development, potentially reducing human error, cutting costs, and improving efficiency across drug repurposing, discovery, and clinical trial monitoring. This AI-driven strategy is expected to accelerate growth, deliver shareholder value, and maintain Conduit's competitive edge in the pharmaceutical sector.